Modeling and Simulation of Triclosan Kinetics and Distribution in Humans Using a PBPK Model by Maharjan, Samee et al.
Modeling and simulation of Triclosan kinetics and distribution in 
humans using a PBPK model 
Samee Maharjan¶, Roshan Sharma¶, Trine Husøy‡, Hubert Dirven‡, Monica Andreassen‡, Bernt Lie¶  
¶ Telemark University College, Norway  
‡ Dept. of Food, Water and Cosmetics; Norwegian Institute of Public Health (NIPH) 
 
 
Abstract 
Triclosan is an antibacterial additive which is widely 
used in personal care products (PCPs) such as soaps, 
perfumes etc. Previous studies have indicated that 
triclosan might have potential to adverse effects on the 
human health. Some traces of triclosan are found in 
human plasma and milk at a concentration which is 
likely to be related to the use of PCPs. 
In this study, a Physiologically Based 
Pharmacokinetic or Toxicokinetic (PBPK/TK) model 
is developed to assess the concentration of triclosan in 
human organs after exposure through the skin (dermal) 
or the oral canal. The absorbed chemical is 
metabolized in the liver and leaves as conjugates and 
then excreted through kidney in the urine. The 
simulation is done using MATLAB. Lastly, the 
developed model is fitted using least square techniques 
in MATLAB using synthetic data generated from the 
model itself with or without the addition of random 
noise. 
Keywords:     Triclosan, PBPK, Model fitting 
1 Introduction 
The excess use of chemicals in PCPs, it has attracted 
concern from pharmacists, chemists and 
environmentalists. Human exposure to common 
household chemicals is a potential health risk. 
Triclosan is one of these chemicals which are widely 
used as an antibacterial compound in cosmetic 
products. Triclosan is an off white chlorinated aromatic 
compound, which consists of two benzene rings linked 
by an oxygen atom, with three chlorine atoms and a 
hydroxyl group attached. It was first used in 1970s in 
hospitals since then become a widely used anti 
bacterial agent. While people who use triclosan 
products daily have higher levels of the chemical in 
their bodies, even consumers who do not use triclosan 
on their skin are exposed to it through food, water, and 
even household dust1.   
Physiologically Based Pharmacokinetic 
/Toxicokinetic (PBPK/TK) Models are commonly used 
in the pharmaceutical and toxicological sciences to 
understand the distribution of chemicals in the human 
body. Mathematically based differential equations are 
used to depict pharmacokinetic processes in terms of 
physiological and biochemical parameters. PBPK/TK 
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modeling can be taken as an example of using simple 
modeling technique for model development and then 
simulate accordingly. These models are widely used in 
the field of toxicology and risk assessment. In (Mielke 
& Gundert-Remy, 2012), three different case studies 
for two chemicals are presented. One case study is 
done for the effect of Bisphenol A on the newly born 
child, whereas other two are the assessing the 
concentration of Bisphenol A and Coumarin in the 
body organs through dermal penetration. For all three 
case studies a PBTK model is used with required 
physiological and chemical parameters.  Basically 
these models described the distribution of a chemical, 
in the human organs according to its absorption, 
metabolism and excretion. The results from such 
simulations are basically the chemical concentrations 
that will eventually stay in the body after exposure and 
distribution to target organs for toxicity. A PBPK/TK 
model comprises the physiology of the body and the 
toxicokinetic properties of the chemical. It is not 
possible to determine the risk of the chemical based on 
the modeling. To do that we need real exposure data 
and compare this with the toxicity of the compound. If 
the human exposure are low, the risk is also low, 
independent of the knowledge of the distribution at a 
certain dose. 
In this paper, we develop a PBPK/TK model for 
assessing the distribution of triclosan in the human 
organs after exposure through both the oral and the 
dermal route. In Section 2, a description of the system 
under study is given. In section 3, a detail of model 
development using species balance for each organ is 
shown. All the simulation results are given in Section 4 
whereas sensitivity analysis and model fitting for 
uncertain parameters are discussed in Section 5. Lastly 
the results of the paper are discussed in section 6.     
2 System Description                                              
Studies show that after almost 2 hours of dermal 
application in rats, traces of triclosan are seen in the 
blood system. By 24 hours, 23 % of the applied dose 
appeared in blood whereas remaining dose is resided in 
the skin. Metabolism of triclosan mainly takes place in 
the liver but a small amount is also metabolized in the 
skin itself. The percentage of glucuronide are found to 
be higher than that of sulfate  (4.1% vs. 0.9 % at 24 
hrs)  in blood, this suggests that most of the formed 
sulfate  remains in skin but glucuronide diffuse more 
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readily into blood by virtue of hydrophilicity. 
Absorption of triclosan in the human skin is 
approximately 5 times slower than in the rats. This is 
because rats possess thinner stratum corneum2 and 
larger number of hair follicles than humans (Moss, 
Howes, & Williams, 2000) . For oral application, the 
triclosan dose is directly transported to the liver where 
metabolism takes place before entering the systemic 
circulation through first pass metabolism. Thus, the 
amount of free triclosan found in blood after oral 
exposure is less than the amount after dermal 
application for the same dose. The ratio between the 
two conjugates varies from species to species. 
Different studies show that for humans, almost all the 
applied dose is converted into conjugates with 
approximately 90% as glucuronides and 10% as 
sulfates. In contrast, 78-90% of the triclosan was found 
as sulfate conjugates in mice (Rodricks, Swenberg, 
Borzelleca, Maronpot, & Shipp, 2010). Triclosan 
excreted predominantly as its conjugates. Irrespective 
to the route of application, the major route of 
elimination in humans is through urine while in rats 
triclosan is excreted in faeces. Triclosan in rat will 
therefore undergo entherohepatic circulation3. In the 
intestine of rats the conjugated triclosan is de-
conjugated by glucuronidases and sulphatases, and the 
free triclosan is re-absorbed (Moss et al., 2000). 
Metabolism of Triclosan 
  The main metabolites of triclosan are the 
conjugation products triclosan sulfate and triclosan 
glucuronide Figure 1. The conjugation of triclosan is 
described as follows. A family of enzymes known as 
SULT (sulfotransferase) catalyze the transfer of a 
sulfonate group (-SO-3 ) from PAPS 
(3'phosphoadenosine-5'-phosphosulfate) to triclosan, 
forming the conjugate triclosan sulfate with the release 
of PAP (3-phosphoadenosine-5-phosphate). Denoting 
triclosan by T and triclosan sulfate by TS, we can write 
the overall reaction as, 
      +                +     . 
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 the circulation of  substances from the liver to the bile, 
followed by entry into the small intestine, absorption by 
the enterocyte and transport back to the liver. 
 
Figure 1: Metabolism of triclosan into glucuronides 
and sulfates (After Fang et al., 2010). 
Similarly, an enzyme known as UGT (Uridine 5'-
diphospho-glucuronosyl transferase = UDP-
glucuronosyl transferase) catalyzes the transfer of the 
glucuronic acid component of UDP-glucuronic acid to 
triclosan, forming the conjugate triclosan glucuronide 
as well as a residual of UDP-glucuronic acid. Denoting 
UDP-glucuronic acid by G, the conjugate triclosan 
glucuronide by TG, and the residual of UDP-glucuronic 
acid by , we can write the overall reaction as,   +              +   .  
In both cases, triclosan (T, substrate) is absorbed on 
the enzyme surface and is inserted into the active site. 
Provided that triclosan has been absorbed into the 
active site, we assume that a co-substrate (PAPS or G) 
also is adsorbed at the active site, forming a 
substrate/co-substrate complex. Next, a reaction takes 
place in this complex formed at the active site, and 
conjugated triclosan (TS or TG) is formed together with 
a co-product (PAP or ) and these then desorbs from 
the active site. Under the conditions of constant 
enzyme concentration and constant co- factor 
concentration, the overall reaction rate referring to 
triclosan can be written as,      =       c c +   ,  , 
where [   ] is given in mole/(time and protein mass), 
and j   S,G}. The individual reaction rates are thus:     =      ,  c c +   ,      =      ,  c c +   ,  
In (Wang, Falany, & James, 2004), the rate 
constants are given for human liver as  From Table 1 it 
should be observed that the molar rates of generation 
are given as n   =      .m ,  , 
where m ,  is the relevant mass of protein in the 
liver. Sulfonation takes place in the human liver 
cytosol while glucuronidation takes place in the liver 
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microsomes. Due to the fact that sulfatation occurs in 
cytosol and glucuronidation occurs in membranes of 
the liver, the protein mass for the two enzymes would 
differ (Wang et al., 2004). These protein masses is 
needed because the    �� and KT is taken from  human 
in vitro liver studies. If we had data from formation of 
conjugates in human blood, we would not need these 
factors. 
 Ideally, we would like to relate m ,  to the mass m  of the liver as an organ instead (hepatic mass), in 
other words to    satisfying m , =    m  . 
In (Cubitt, Houston, & Galetin, 2009), the hepatic 
cytosolic scaling factor was found in the range   ,    45,134} mg protein in liver cytosol per g of liver, with 
a mean weighted value   ,  = 80.7× 10-3. They also 
report a typical fraction protein in intestine cytosol per 
g intestine to be   ,  = 18 ×10-3. It should be observed 
that the rate numbers given in Table 1 do not 
necessarily carry over from liver to intestine. In (Barter 
et al., 2007), experimental results are cited in the 
range   ,    19,77} mg protein in livermicrosomes 
per g of liver. The value probably varies among 
individuals, with age, and by gender. A possible useful 
value may be    ,  = 30 ×10-3. In (Johnson, Tucker, 
Tanner, & Rostami-Hodjegan, 2005) variation in liver 
size (m ) for humans is discussed. 
 
Table 1: Michaelis-Menten reaction parameters for 
triclosan metabolism in human liver (Wang et al., 
2004). 
   , ,     mo        , ,     mo  min m    o  in  
Sulfonation (S) 8.5±3.2 95.1±28.4 
Glucuronidation
(G) 
107±2.2 739±163 
3 Model development 
Figure 2 illustrates the topology of a network of 
organs describing the transport of chemicals from its 
absorption through the skin and/or the GI tract to its 
excretion through the kidney. After absorbing chemical 
through the skin, triclosan along with its conjugates 
passes through the skin and mix with the central blood 
system. 
The central blood system then transports these 
chemicals into almost every organ. The circulation 
process continues until the entire dose intake has been 
eliminated. The excretion of chemical is via the kidney 
through urine. Triclosan is relative hydrophilic and 
does not accumulate in the body and is rapidly 
metabolized and excreted. Thus we can assume that the 
membrane between tissue and capillary of an organ is 
of no barrier. For this kind of chemicals, their kinetics 
can be best described by a perfusion-rate-limited 
kinetics. A single compartmental model is used for 
model development process. 
 
Figure 2: Flow of chemical intake (Beard, 2012). 
 
Species Balance 
The general species balance in molar form, dn d = n   − n   + n    . 
Here, n   = Number of moles generated of species j. n   = Influx number of moles per unit time of species j. n   = Efflux number of moles per unit time of species 
j. 
For non metabolic organs 
The number of moles expressed in the form of 
concentration as, n   =    c   n   =   c ∗. 
Here c ∗ =       ,  is the partition coefficient and as 
there will be no any chemical reformation,  n   =   
thus the reaction can be described by the equation, dn d =  =   (c  − c ∗). 
Here j = {free triclosan (T), triclosan sulfate (TS), 
triclosan glucuronide (TG)}. 
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For metabolic organs 
For the liver and the skin where there is breakdown 
of free triclosan into its conjugates, the reactions can be 
represented by, dn , d =    (c ,  − c , ∗ ) − n  ,  + n  2  dn  , d =     c  ,  − c  , ∗  + n   ,   dn  , d =     c  ,  − c  , ∗  + n   ,   
Here 'k' is for the liver and the skin. n  2  is the amount 
of chemical applied either through the skin or the 
mouth. 
The excretion is through the kidney as urine. n  , 2 =    2 c ,    ∗   
Flow Junction 
The flow topology has one junction at the inlet to 
the blood pool. For this junction, no matter is 
accumulated. Steady state species balances for this 
junction lead to: n  ,   =  n  ,    + n  ,   + n  ,   + n  ,   + n  ,   + n  ,   + n  ,   + n  ,     n  ,   =  n  ,    
Here subscript "k" denotes the possible substrate i.e. 
free triclosan, glucuronide and sulfate. 
4 Simulation and Analysis 
Model parameter 
Table 2 shows the standard model parameters used 
for PBPK model development for human. All the 
standard parameters are extracted from (Mielke et al., 
2011). Additional parameters that are used in 
implementing metabolism and excretion of triclosan in 
human body are given in Table 1. So far no specific 
data for skin is provided, thus 20% of corresponding 
parameter of liver is used for reaction kinetics in the 
Skin. The chemical excretion coefficient from kidney 
to urine is estimated from the standard chemical 
excretion coefficient of rats by using the tissue volume 
ratio for scaling.  
Tissue volume of kidney for rats = 2.77 ml  
Tissue volume of kidney for humans = 310 ml     2  for rats = 0.490 ml/s (Beard, 2012)   2  for human = 0.490*310/2.77 = 54.8 ml/s  
Effective permeation for the conjugates is different 
from their parent chemical. As there is lack of the exact 
value for the effective permeation of triclosan 
conjugates, a chemical excretion coefficient of parent 
compound which is scaled by 4 is used. 
 
Table 2: Standard parameters for human (Mielke et 
al., 2011) . 
Organ  
 
Volume 
of tissue 
Vt [  ] Flowrate   /    Partition Coefficient 
 [    [-] 
No. Name 
   
1 Brain 1.45 46.8 0.73 
2 Muscle 29.2 65.8 0.29 
3 Bone 9.33 7.8 0.23 
4 Fat 18.2 19.5 4.20 
5 Skin 2.7 20 0.77 
6 Kidney 0.31 74.1 0.51 
7 Small Intestine 3.7 20 0.57 
8 Liver 1.8 99.5 0.57 
9 Lung 1.432 353.5 1.16 
10 Blood pool 5 353.5 - 
 
Operating condition 
The following operating conditions are used in the 
model:  Initial states: all are zero.  Body weight (bw):73 kg  Chemical dose 0.1 g / kg bw is supplied 
continuously for 2 hours. 
Simulation results 
The simulations are carried out using MATLAB for 
both oral and dermal application. The level of 
concentration in the simulation is presented as the 
number of accumulated moles  of chemicals (T, TS and 
TG) in each organ scaled by the mass of administered 
chemical. Figure 3, Figure 4 and Figure 5 contains the 
information for free triclosan, triclosan glucuronide 
and triclosan sulfate respectively for human organs. 
Due to relatively high volume and low flow rate, the 
muscles and the fats contain high number of free 
triclosan and conjugates. As their plots are not 
compatible with the plots of remaining organs, a 
separate  is used to show the level of chemicals in 
them. The difference in the level triclosan and its 
conjugates in the human blood after the oral and 
dermal exposure are shown in Figure 7. 
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Figure 4: All accumulated molar mass of  triclosan glucuronide scaled by total 
mass of administered chemical in human. 
Figure 3: All accumulated molar mass of  free triclosan scaled by total mass of 
administered chemical in human. 
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5 Parameter Estimation 
5.1 Sensitivity analysis 
  Morris method is used for the sensitivity analysis 
of uncertain parameters. Here the concentration of free 
triclosan and its two conjugates in the liver are the 
chosen output for the analysis. The sensitivity analysis 
is performed by calculating the elementary effect (EE) 
for each uncertain parameter. The sensitivity measure 
using Morris method is only qualitified not quantitified 
(how much a given factor is more important than 
others).Let the parameters be Pi where i = {1.....9} for 
9 uncertain parameters and output as the function of 
these parameters as f (Pi) .Then elementary effect for 
first parameter, can be calculated as, 
   1 =      +∆ ,   .....     −         ,   .....    ∆  . 
Here j = {1, 2.......k} if 'k' number of random values 
for first parameter are considered within its upper and 
lower bound. So for 100 random values, there will be 
100 EEs for the first parameter which will be later 
normalized. 
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Figure 5: All accumulated molar mass of  triclosan sulfate scaled by total 
mass of administered chemical in human. 
 
Figure 6: All accumulated molar mass scaled by total mass of administered chemicals in the muscles and 
the fats. 
Fats 
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If standard deviation is relatively small, the effect of 
that particular parameter on the output is ''mildly 
nonlinear''. If the standard deviation is relatively large, 
then the effect of the parameter on the output is 
''strongly non linear'' (Ekstrom, 2005). Overall large 
measure of the mean of the EEs indicates a parameter 
with an important (overall) influence on the output. A 
high measure of the standard deviation of EEs may 
indicate that a parameter is highly interacting with 
other parameters. It may also indicate that the effect of 
this parameter is non linear (Morris, 1991).  
Figure 8 shows the standard deviation of all 
uncertain parameters. 
 
5.2 Model fitting 
For least square method which is a widely used way 
to fit parameters, with following procedures: take 
differences between predicted values of y and observed 
values of y, square them and add up all the quantities 
for each of the data points. With data points (xi, yi), the 
predicted value of y is g (xi; a), and the sum of squares 
is  
 
2
1
( ) ( ( ; ))
N
i i
i
L y g x a a
  
Obviously, the sum of squares depends on the 
parameter vector a, so we write L as a function of a. 
Figure 7: All accumulated molar mass scaled by total mass of administered 
chemicals in the human blood for the oral and dermal application. 
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The task is to find the minimum of L (a) over different 
values of a. In general, this is not straightforward, 
unless the function g is linear. 
Due to the lack of experimental data, synthetic data 
from the simulation with all parameter are sampled 
every hour and placed as predicted output. According 
to the sensitivity analysis, parameter P5 have almost 
same standard deviation in all three outputs whereas P7 
and P8 show high standard deviation so these three 
parameters are taken for the model fitting. Assuming 
that these parameters are unknown ones, the model is 
fitted with curve of synthetic data. The analysis is done 
for the concentration of free triclosan and its two 
conjugates in the blood as it will be easier to get 
sampling data from the blood. First simulation is done 
without adding any external noise to the predicted 
output (Figure 9) whereas second simulation is done 
with the addition of random noise into the predicted 
output (Figure 10). The random noises are generated 
between 0 to approximately 5% of peak value of 
calculated output when there was no noise. 
6 Results and Discussion 
The concentration of free triclosan seems to be very 
high during first few hours of exposure, but is rapidly 
distributed and excreted. The organ concentration of 
triclosan glucuronide was higher than that of triclosan 
sulfate. After exposure, the concentration of triclosan 
glucuronide drops down faster than triclosan sulfate so 
after few hours the concentration of triclosan sulfate is 
higher. The pattern is same for almost all the organs. 
There is difference in the concentration level for the 
oral and the dermal route. In most of the organs, the 
concentration of free triclosan is relatively low whereas 
those of conjugates are relatively higher for the dermal 
application than oral application. The skin contains 
extremely high number of moles of free triclosan than 
other organs if the route of application is dermal. The 
Michaelis-Menten reaction parameters for triclosan 
metabolism in human skin shows higher standard 
deviation that means small deviation in these 
parameters can affect the model drastically. This might 
be due to the fact that the sensitivity analysis is done 
for dermal application in which free triclosan is firstly 
metabolized in the skin. 
Simulations show that within 15 hours of 
application 90% of the administered chemicals are 
metabolized into its conjugates. For no noise or very 
little noise in the sampled output model fitting works 
fine for 3 unknown parameters but there was some 
deviation from predicted output when noise is 
increased. So we cannot be sure about using model 
fitting for those models where there is possibility of 
high noise. 
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Figure 9: Synthetic measurements vs. model fitted output in the blood. 
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7  Conclusion 
In this study, we demonstrate the concentration level 
of triclosan and its conjugates in the human organs 
with PBPK modeling. Large organs like muscles and 
fats contain relatively high concentration than other 
remaining organs. Due to the unavaibitlity of verified 
and experimental data the validation of developed 
model was not possible to be done. 
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